In light of these premises, it seems clear that more efficient breast cancer treatment strategies, based on innovative technologies that target the HER2 molecular marker, could represent valid and effective approaches for HER2+ breast cancer therapy. The gene discussed is ERBB2; the disease is breast cancer.